Targeted Cancer Treatment: McGill University Researchers Develop Nanoparticle-Based Immunotherapy
Original framing: “Engineered nanoparticles could deliver better targeted cancer treatment to lymph nodes” — Phys.org
The study's findings are based on preclinical research and have not yet been tested in human trials. However, the results suggest that engineered nanoparticles may be a promising approach to delivering targeted cancer treatment.
The McGill University research team's development of engineered nanoparticles for targeted cancer treatment is a significant breakthrough in cancer immunotherapy.
However, its impact will depend on its accessibility and affordability for patients worldwide. To ensure that this innovation benefits patients globally, it is essential to address the structural and systemic barriers to accessing cancer treatment, foster interdisciplinary research, and develop sustainable and equitable healthcare solutions that prioritize patient well-being and social justice. The study's findings also highlight the need for more culturally sensitive healthcare solutions and the importance of collaboration between Western and Indigenous approaches to healthcare.